Humanigen, Inc. Is Effective Today

August 7, 2017

BRISBANE, Calif. – August 7, 2017 – Humanigen, Inc. (OTCQB: HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced that its new name is effective.

The company is now operating as Humanigen and will begin trading on the OTCQB market under the ticker symbol “HGEN” today.

“We are Humanigen, a renewed company, focused on achieving corporate and clinical milestones and delivering value for our stakeholders,” said Cameron Durrant, MD, chairman and CEO. 

As Humanigen, the company expects to continue its transformation, executing on key priorities and anticipated milestones including:

  • New Drug Application (NDA) submission for benznidazole in Chagas disease, a neglected tropical disease, to the U.S. Food and Drug Administration (FDA) in first quarter 2018

  • Submission for both rare pediatric designation and orphan drug designation for lenzilumab in Juvenile Myelomonocytic Leukemia (JMML)

  • Development of an interim analysis of the lenzilumab Phase 1 trial in Chronic Myelomonocytic Leukemia (CMML)

  • Up-listing to a national securities exchange and ongoing work to improve the capital structure

The CUSIP number for Humanigen’s common stock is 444863104. The name change does not affect the rights of the company's stockholders. No action is required by existing stockholders with respect to the name change, and certificates representing outstanding shares of the company’s common stock issued under the former name will not need to be exchanged.

For more information, visit


About Humanigen   

Humanigen, Inc. is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). For more information, visit


Forward-Looking Statements  

This release contains forward-looking statements that are intended to be subject to protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations as to the timing for submission of our NDA for benznidazole and our expectations for executing on the other key priorities and anticipated milestones described above. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, our lack of profitability and the need for additional capital to operate our business as a going concern; the uncertainties inherent in the development and launch of any new pharmaceutical product; the acceptability to FDA of a 505(b)(2) development pathway for approval of benznidazole using data drawn from previously conducted studies; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.




Mike Cole

O: 949-259-4988

C: 949-444-1341



Lisa Guiterman

O: 301-217-9353

C: 202-330-3431

Source: Humanigen, Inc.

Released August 7, 2017

  • Twitter

©2020 Humanigen, Inc.  All rights reserved